In his oral evidence, Professor Howard Thomas agreed that he had given the Glasgow Symposium the message that there would be problems in the future with hepatitis, fibrosis and cirrhosis. Read more about In his oral evidence, Professor Howard Thomas agreed that he had given the Glasgow Symposium the message that there would be problems in the future with hepatitis, fibrosis and cirrhosis.
A clinical study done by Dr Dormandy with the US counterparts demonstrated that haemophiliacs treated exclusively with the new concentrates suffered raised transaminases more commonly than UK patients who were treated with cryoprecipitate. Read more about A clinical study done by Dr Dormandy with the US counterparts demonstrated that haemophiliacs treated exclusively with the new concentrates suffered raised transaminases more commonly than UK patients who were treated with cryoprecipitate.
Dr Kernoff stated 25% of all Factor VIII used was in the form of cryoprecipitate which was unsatisfactory at the Royal Free Hospital. Read more about Dr Kernoff stated 25% of all Factor VIII used was in the form of cryoprecipitate which was unsatisfactory at the Royal Free Hospital.
At the meeting of the Haemophilia Working Party, it was agreed that all registered haemophiliacs on regular treatment should be fully screened for hepatitis at their regular three-month visits to the major haemophilia centres. Read more about At the meeting of the Haemophilia Working Party, it was agreed that all registered haemophiliacs on regular treatment should be fully screened for hepatitis at their regular three-month visits to the major haemophilia centres.
The NANBH risks associated with Factor 8 concentrates were the subject of discussion at the Haemophilia Working Party's meeting. Read more about The NANBH risks associated with Factor 8 concentrates were the subject of discussion at the Haemophilia Working Party's meeting.
In his letter to Mr Jones, Dr Kernoff referred to the Royal Free policy to attempt to maintain individual patients on particular brands to minimise the risk of hepatitis. Read more about In his letter to Mr Jones, Dr Kernoff referred to the Royal Free policy to attempt to maintain individual patients on particular brands to minimise the risk of hepatitis.
In his letter to Dr Colvin, Dr Kernoff described NANBH as a serious disease with long-term consequences. Read more about In his letter to Dr Colvin, Dr Kernoff described NANBH as a serious disease with long-term consequences.
Dr Kernoff suggested that cryoprecipitate, although relatively cheap to produce, had serious clinical disadvantages and that the shortfall in NHS concentrates had to be met by buying commercial concentrate. Read more about Dr Kernoff suggested that cryoprecipitate, although relatively cheap to produce, had serious clinical disadvantages and that the shortfall in NHS concentrates had to be met by buying commercial concentrate.
At the meeting, Dr Rankin commented their allocation had been reduced from 100 to 65 bottles of factor VIII due to shortage. This forced his reference centre to begin transferring patients to other Centres at a much younger age. Only half of their patients on home therapy could be treated with concentrate. Read more about At the meeting, Dr Rankin commented their allocation had been reduced from 100 to 65 bottles of factor VIII due to shortage. This forced his reference centre to begin transferring patients to other Centres at a much younger age. Only half of their patients on home therapy could be treated with concentrate.
At the meeting, Dr Kernoff stated Royal Free aimed to switch home treatment patients from cryoprecipitate to concentrate with currently (September 1978) still half of the home treatment patients still using cryoprecipitate which was deemed unacceptable. Read more about At the meeting, Dr Kernoff stated Royal Free aimed to switch home treatment patients from cryoprecipitate to concentrate with currently (September 1978) still half of the home treatment patients still using cryoprecipitate which was deemed unacceptable.